Brachytherapy — head and neck cancer

  • Don R. Goffinet
Part of the Cancer Treatment and Research book series (CTAR, volume 32)

Abstract

Interstitial implantation of radioactive sources, brachytherapy, is frequently used in the treatment of head and neck cancers. Implanting radioactive isotopes is a means of not only obtaining high localized radiation doses to the tumor bed, but also minimizing normal tissue injury, since the radiation is delivered only to the area of neoplastic involvement. Brachytherapy has been practiced for many years; 226-Radium needles or 222-Radon sources were used initially [1], but it was not until the last decade that interstitial implants have become more popular, due to several factors. The availability of new isotopes, such as 125-Iodine (125I) for permanent implantation and 192-Iridium (192Ir) for removable procedures, has allowed more complex interstitial procedures to be performed, while the latter isotope, by making afterloading possible, has minimized radiation doses to medical personnel [2–4]. Computerized dosimetry has enabled implants to be pre-planned, so that ideal symmetry and proper placement of sources may be determined prior to the procedure, while post-implantation dosimetry not only allows radiation dose rates to be calculated with removable implants, but also provides a method of correlating results and complications with radiation doses [5]. New implant techniques, to be discussed, have also contributed to our ability to perform these procedures effectively and safely. In this chapter, the common radioactive isotopes in use today will be described, as will the techniques of implantation and the results of treatment of selected primary sites and cervical lymph nodes.

Keywords

Catheter Microwave Mold Radium Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Martin, C.L., Martin, J.A. 1965. Treatment of epithelioma of the lateral oropharynx with low intensity radium needle implants. A.J.R. 93: 7–19.Google Scholar
  2. 2.
    Kim, H., Hilaris, B. 1975. Iodine-125 source in interstitial tumor therapy. A.J.R. 123: 162–169.Google Scholar
  3. 3.
    Vikram, B., Hilaris, B.S., Anderson, L., et al. 1983. Permanent Iodine-125 implants in head and neck cancer. Cancer 51: 1310–1314.PubMedCrossRefGoogle Scholar
  4. 4.
    Goffinet, D.R., Martinez, A., Pooler, D. et al. 1981. Brachytherapy renaissance. Front. Radiat. Ther. Oncol. 15: 43–57.Google Scholar
  5. 5.
    Sandor, J., Palos, B., Goffinet, D.R. et al. 1979. Dose calculations for planar arrays of 192Ir and 125I seeds for brachytherapy. Appl. Radiol. 8: 41–44.Google Scholar
  6. 6.
    Fee, W.E., Jr., Goffinet, D.R., Fajardo, L.F. et al. 1985. Safety of 125Iodine and 192Iridium implants to the canine carotid artery: preliminary report. Laryngoscope 95: 317–320.PubMedCrossRefGoogle Scholar
  7. 7.
    Goffinet, D.R., Martinez, A., Fee, W.E. et al. 1983. Intraoperative pterygo-palatine 125I seed implants. Int. J. Radiat. Oncol. Biol. Phys. 9: 103–106.PubMedCrossRefGoogle Scholar
  8. 8.
    Goffinet, D.R., Martinez, A., Fee, W.E. 1985. 125I vicryl suture implants as a surgical adjuvant in cancer of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 11: 399–402.PubMedCrossRefGoogle Scholar
  9. 9.
    Goffinet, D.R., Martinez, A., Pooler, D. 1981. 125I seed implantations as a surgical adjuvant in head and neck cancers. In: Kominierte Chirurgtische und Radiologische Therapie Maligner Tumoren (M. Wannenmacher, ed.). Urban & Schwarzenberg, München, pp. 46–48.Google Scholar
  10. 10.
    Gutin, P.H., Phillips, T.L., Hosobuchi, Y. et al. 1981. Permanent and removable implants for the brachytherapy of brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 7: 1371–1381.PubMedCrossRefGoogle Scholar
  11. 11.
    Gilbert, E.H., Goffinet, D.R., Bagshaw, M.A. 1975. Carcinoma of the tongue and floor of the mouth: fifteen years’ experience with linear accelerator therapy. Cancer 35: 1515–1525.CrossRefGoogle Scholar
  12. 12.
    Goffinet, D.R. 1985. Head and neck brachytherapy emphasizing afterloading removable oropharyngeal implants. In: Head and Neck Cancer 1, (P.B. Chreten, M.E. Johns, O.P. Sherd, E.W. Strong, P.W. Ward, B.C. Decker Inc., Philadelphia, pp. 359–364.Google Scholar
  13. 13.
    Goffinet, D.R., Fee, W.E., Jr. Wells, J. et al. 1985. 192Ir pharyngoepiglottic fold interstitial implants. Cancer 55: 941–948.PubMedCrossRefGoogle Scholar
  14. 14.
    Sealy, R., LeRoux, P.L.M., Hering, E., Buret, E. 1984. The treatment of cancer of the uvula and soft palate with interstitial radioactive wire implants. Int. J. Radiat. Oncol. Biol. Phys. 10: 1951–1955.PubMedCrossRefGoogle Scholar
  15. 15.
    Syed, A.M.N., Puthawala, A., Fleming, P. et al. 1980. Afterloading interstitial implant in head and neck cancer. Arch. Otolarynogol. 106: 541–546.Google Scholar
  16. 16.
    Pierquin, B., Chassagne, D., Baillet, F., Castro, J.R. 1971. The place of implantation in tongue and floor of the mouth cancer. J.A.M.A. 215: 961–963.PubMedCrossRefGoogle Scholar
  17. 17.
    Goffinet, D.R., Martinez, A., Palos, B. et al. 1977. A method of interstitial tonsillo-palatine implants. Int. J. Radiat. Oncol. Biol. Phys. 2: 155–162.PubMedCrossRefGoogle Scholar
  18. 18.
    Fee, W.E., Jr., Goffinet, D.R., Paryani, S., etal. 1983. Intraoperative Iodine-125 implants: their use in large tumors on the neck attached to the carotid artery. Arch. Otolaryngol. 109: 727–730.PubMedGoogle Scholar
  19. 19.
    Puthawala, A.A., Syed, A.M.N., Neblett, D. et al. 1981. The role of afterloading iridium (192Ir) implant in the management of carcinoma of the tongue. Int. J. Radiat. Oncol. Biol. Phys. 7: 407–412.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1987

Authors and Affiliations

  • Don R. Goffinet

There are no affiliations available

Personalised recommendations